Mechanism of action
According to the manufacturer of the drug, Kagocel induces the production of α- interferons and β-interferons with high antiviral activity. Kagocel mobilizes all groups of cells in the body that take part in the antiviral response: T-lymphocytes and B-lymphocytes, macrophages, granulocytes, fibroblasts, Endothelium|endothelial cells. The titer of interferon in the blood serum reaches its maximum values in 48 hours after one dose of Kagocel is taken orally. The body's interferon response to the oral administration of Kagocel is characterized by prolonged (up to 4-5 days) circulation of interferon in the bloodstream.
In the course of experiments conducted over 16 years, 14 undesirable side effects were identified, the possibility of which is included in the instructions for medical use of the drug. Contraindications to the use of medication include individual hypersensitivity to its components, lactase deficiency, lactose intolerance, glucose-galactose malabsorption, pregnancy and lactation, as well as pediatric use with children under the age of three.
The main safety concern is caused by Kagocel’s active substance copolymer gossypol (a natural polyphenol, toxic in its free form), the contraceptive proprieties of which were considered an issue in the past. However, recent studies have shown that gossypol loses its toxic properties after the crosslinking of its molecules with a polymer carrier. This principle lies at the core of Kagocel, in which gossypol is bound to a polymer carrier of carboxymethyl cellulose. Studies conducted on animals showed that Kagocel does not adversely affect reproductive function and is safe to use  .
- Popov, A.F.; Dmitrenko, K.A.; Shchelkanov, M.Y; Simakova, A.I. "Combined therapy of influenza with antiviral drugs with a different mechanism of action in comparison with monotherapy". Journal of Pharmaceutical Sciences and Research.
- Borovskaya, T.G. "Preclinical and Clinical Evidence of Safety of Antiviral Drug with Immunomodulatory Activity". Serbian Journal of Experimental and Clinical Research.
- Kharlamova, F.S.; Uchaikin, V.F.; Kladova, O.V.; Sergeeva, E.M.; Nesterenko, V.G. "CLINICAL AND PREVENTIVE EFFICACY OF INTERFERON INDUCTOR IN VIRAL RESPIRATORY TRACT INFECTIONS IN CHILDREN YOUNGER PRESCHOOL AGE". Педиатрическая фармакология.
- Sologub, T. V.; Tsvetkov, V. V. "Kagocel in the therapy of influenza and acute respiratory viral infections: Data analysis and systematization from the results of preclinical and clinical trials". Terapevticheskii Arkhiv.
- Galegov, G. A.; Narovlianskiĭ, A. N.; Sarymsakov, A. A.; Mezentseva, M. V.; Polonskiĭ, V. O.; Gomes, L. A.; Nesterenko, V. G.; Ershov, F. I. "[The effect of Kagocel on herpes virus reproduction]". Voprosy Virusologii. 47 (4): 42–44. ISSN 0507-4088. PMID 12271726.
- Kenar, James A. (2006-04-01). "Reaction chemistry of gossypol and its derivatives". Journal of the American Oil Chemists' Society. 83 (4): 269–302. doi:10.1007/s11746-006-1203-1. ISSN 1558-9331.
- Khaitbaev, A. Kh.; Aslanov, Kh. A.; Auelbekov, S. A.; Khaitbaev, Kh. Kh.; Saiitkulov, S. M. (1994-01-01). "Synthesis of new imino derivatives of gossypol". Chemistry of Natural Compounds. 30 (1): 40–41. doi:10.1007/BF00638417. ISSN 1573-8388.
- Borovskaya, T. G. "Safety of the Russian antiviral drug Kagocel". Terapevticheskii Arkhiv. PMID 29260752.
- Borovskaya, T. G.; Poluektova, M. E.; Vychuzhanina, A. V.; Mashanova, V. A.; Shchemerova, Yu A. (2017). "Experimental Assessment of the Effect of Kagocel on Reproductive Function in Pubertal Male Rats". Bulletin of Experimental Biology and Medicine. 163 (2): 214–217. doi:10.1007/s10517-017-3769-z. ISSN 1573-8221. PMID 28726202.
- Zhanataev, A. K.; Borovskaya, T. G.; Shcherbakova, B. S.; Rudoi, B. A.; Vychuzhanina, A. V.; Grigor'eva, V. A.; Kamalova, S. I.; Durnev, A. D. "Evaluation of Kagocel Genotoxicity". Bulletin of Experimental Biology and Medicine. 166 (6): 731–734. doi:10.1007/s10517-019-04428-w. ISSN 1573-8221. PMID 31020577.